Medium-term outcomes of active surveillance for localised prostate cancer

European Urology

Volumn 64, Issue 6, 2013, Pages 981-987

  Selvadurai, Elizabeth D ^a,b   Singhera, Mausam ^a,b   Thomas, Karen ^a   Mohammed, Kabir ^a   Woode Amissah, Ruth ^b   Horwich, Alan ^a,b   Huddart, Robert A ^a,b   Dearnaley, David P ^a,b   Parker, Chris C ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Active surveillance; Outcomes; Prostate cancer

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROBABILITY; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; TUMOR BIOPSY; WATCHFUL WAITING;

ACTIVE SURVEILLANCE; OUTCOMES; PROSTATE CANCER;

AGED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84887405044     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.020     Document Type: Article

References (26)

1. G.P. McVey, S. McPhail, S. Fowler, G. McIntosh, D. Gillatt, and C.C. Parker Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry BJU Int 106 2010 1161 1164
2. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
3. J. Tosoian, B. Trock, and P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
4. M.S. Soloway, C.T. Soloway, and A. Eldefrawy Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831 835
5. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670
6. R.C.N. Van den Bergh, H. Vasarainen, and H.G. van der Poel Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study BJU Int 105 2010 956 962
7. M. Bul, X. Zhu, and R. Valdagni Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597 603
8. R.C.N. Van den Bergh, S. Roemeling, and M.J. Roobol Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1 8
9. A. Adamy, D.S. Yee, and K. Matsushita Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477 482
10. M.A. Dall'era, P.C. Albertsen, and C. Bangma Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976 983
11. N. Van As, A. Norman, and K. Thomas Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance Eur Urol 54 2008 1297 1305
12. M. Roach, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Rad Oncol Biol Phys 65 2006 965 974
13. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
14. M. Soloway, and M. Roach Prostate cancer progression after therapy of primary curative intent. A review of data from the prostate-specific antigen era Cancer 104 2005 2310 2322
15. T.J. Wilt, M.K. Brawer, K.M. Jones PIVOT study group Radical prostatectomy versus observation for localised prostate cancer N Eng J Med 367 2012 19 203 213
16. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer v.3. National Comprehensive Cancer Network Web site. http://www.nccn.org/ professionals/physiciangls/fguidelines.asp#site.
17. N. Van As, N.M. De Souza, and S.F. Riches A study of diffusion weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance Eur Urol 56 2009 981 988
18. A. El Hajj, G. Ploussard, and A. de la Taille Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS) BJU Int 111 2013 53 59
19. L. Villa, U. Capitanio, and A. Briganti The number of cores taken is a major predictor of insignificant prostate cancer in patients diagnosed with a single microfocus at initial biopsy: implications for the selection of candidates suitable for active surveillance J Urol 189 2013 854 859
20. M.C. Smaldone, J.E. Cowan, P.R. Carroll, and B.J. Davies Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort J Urol 183 2010 138 144
21. G. Ploussard, E. Xylinas, and L. Salomon The role of biopsy core number in selecting prostate cancer patients for active surveillance Eur Urol 56 2009 891 898
22. U. Capitanio, P.I. Karakiewicz, and L. Valiquette Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer Urology 73 2009 1087 1091
23. S.P. Porten, J.M. Whitson, and J.E. Cowan Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance J Clin Oncol 29 2011 10 2795 2800
24. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228 234
25. Y. Krakowsky, A. Loblaw, and L. Klotz Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics J Urol 184 2010 131 135
26. H.B. Carter, A. Kettermann, and C. Warlick Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359 2365